Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study Meeting Abstract
| Authors: | Patel, K.; Ramchandren, R.; Maris, M.; Lesokhin, A. M.; von Keudell, G. R.; Cheson, B. D.; Zonder, J.; Seymour, E. K.; Catalano, T.; Lin, G. H. Y.; Uger, B.; Petrova, P. S.; Roberge, K.; Shou, Y. P.; Iyer, S. P. |
| Abstract Title: | Investigational CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: Update from the ongoing first-in-human dose escalation study |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205606072 |
| DOI: | 10.1182/blood-2020-136607 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 46 -- Source: Wos |
